clearbled
liked
$Dare Bioscience (DARE.US)$ is gearing up to launch its study of Ovaprene, a monthly hormone free women's contraceptive that they have partnership with $BAYER AG (BAYRY.US)$ on. They announced that the FDA has approved the study and expect to enroll mid-2023.
Darė already has FDA approval for Xaciato with which they announced a partnership with $Organon & Co (OGN.US)$ and expect revenues to begin generating in Q4 2022.
This is a promising bio for the patient investor IMO...
Darė already has FDA approval for Xaciato with which they announced a partnership with $Organon & Co (OGN.US)$ and expect revenues to begin generating in Q4 2022.
This is a promising bio for the patient investor IMO...
1
clearbled
voted
Spoiler:
At the end of this post, there is a chance for you to win points!
Happy Monday, mooers! Welcome back to Weekly Buzz, where we review the news, performance, and community sentiment of the selected buzzing stocks on moomoo platform based on search and message volumes of last week! (Nano caps are excluded.)
Part Ⅰ: Make Your Choices
Part Ⅱ: Buzzing Stocks List & Mooers Comments
Three major indices moved upward, R...
At the end of this post, there is a chance for you to win points!
Happy Monday, mooers! Welcome back to Weekly Buzz, where we review the news, performance, and community sentiment of the selected buzzing stocks on moomoo platform based on search and message volumes of last week! (Nano caps are excluded.)
Part Ⅰ: Make Your Choices
Part Ⅱ: Buzzing Stocks List & Mooers Comments
Three major indices moved upward, R...
57
29
clearbled
reacted to
Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
14
clearbled
voted
$Dare Bioscience (DARE.US)$ So now that the FDA has approved Xaciato, the company has said they are working on finding a partnership to bring it to market. However, many of those potential partners are heavy with cash. Some believe there is a potential that one of these companies could decide to just buy DARÈ rather than partner with them. $SPDR S&P Biotech ETF (XBI.US)$
2
4
clearbled
liked
$Dare Bioscience (DARE.US)$ Looking good for re-entry tomorrow PM. Would like it to hold 1.99 at its lowest otherwise a bigger dip may come.
1
clearbled
liked
$Dare Bioscience (DARE.US)$ everytime we start to move shorts keep digging that ditch deeper ...because at some point we will get the momentum and run...in the meantime I'm avg down and holding
6
clearbled
reacted to and commented on
$Dare Bioscience (DARE.US)$ don't stress any small price drop now...some people always get out at the end of day along with day traders...it's consolidating well right now in preparation for tom
4
3
clearbled
commented on
$Dare Bioscience (DARE.US)$ buyout looming
3
20